Advertisement

Novel Variants and Copy Number Variation in CDH1 Gene in Iranian Patients with Sporadic Diffuse Gastric Cancer

  • Abbas Moridnia
  • Mohammad Amin Tabatabaiefar
  • Mehrdad Zeinalian
  • Mohammad Minakari
  • Majid Kheirollahi
  • Noushin Afshar Moghaddam
Original Research

Abstract

Introduction

The aim of this study was to survey the nucleotide changes and copy number variations (CNV) in the CDH1 gene in Iranian patients with sporadic diffuse gastric cancer (SDGC).

Materials and Methods

In this study, 28 patients were examined who upon gastrectomy had been diagnosed with SDGC according to the familial history and histopathological criteria which was confirmed by the pathologist. DNA extraction was performed from formalin-fixed paraffin-embedded tissues using a phenol-chloroform method following xylene deparaffinization. Determination of DNA sequence by Sanger was performed using PCR amplification of 16 exons and boundaries of intron/exon of CDH1 gene. Multiplex ligation-dependent probe amplification (MLPA) was performed on patients with pathogenic disorders in the sequence.

Results

In total, patients included 20 males and 8 females. Of all patients, 12 patients were under 45 years old (early onset gastric cancer, EODC) and 16 patients were older. The tumor was diagnosed in the early TNM stage (I, II) in six patients and in late stages (III, IV) in 19 cases. Altogether, 16 variants (three exonic with one new variant and 13 intronic with nine new variants) were found in DNA sequencing of the CDH1 gene in five samples. Also, using MLPA, a new duplication in exon 9 and one deletion in exon 2 were detected in two other patients. Altogether, CDH1 variants were identified in seven out of 28 patients (25%).

Conclusion

Our study revealed several novel somatic variants in the CDH1 gene in Iranian patients with sporadic diffuse GC. Our data supports the hypothesis that mutations in CDH1 gene, and particularly the mutations we describe, should be considered, even in sporadic cases of gastric cancer. The presence of these mutations in patients raises important issues regarding genetic counseling and diagnostic test in DGC patients.

Keywords

Sporadic Diffuse gastric cancer CDH1 Variant Iran 

Notes

Acknowledgements

We sincerely thank the patients and the professional staff of the pathology lab in Al-Zahra hospital (Isfahan, Iran) and also Alaa cancer control center (Isfahan, Iran) for their cooperation in this study.

Funding Information

This research was supported by Isfahan University of Medical Sciences, Isfahan, Iran, with grant number 394479.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Ethical Approval

In this study, all procedures followed in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients for being included in the study.

References

  1. 1.
    Donner I, Kiviluoto T, Ristimäki A, Aaltonen LA, Vahteristo P. Exome sequencing reveals three novel candidate predisposition genes for diffuse gastric cancer. Familial Cancer. 2015;14(2):241–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system, WHO classification of tumours, vol 3. 4th ed. Lyon: IARC Publications; 2010.Google Scholar
  3. 3.
    Oliveira C, Sousa S, Pinheiro H, Karam R, Bordeira–Carriço R, Senz J, et al. Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. Gastroenterology. 2009;136(7):2137–48.CrossRefPubMedGoogle Scholar
  4. 4.
    Kim S, Chung J-W, Jeong T-D, Park Y-S, Lee JH, Ahn JY, et al. Searching for E-cadherin gene mutations in early onset diffuse gastric cancer and hereditary diffuse gastric cancer in Korean patients. Familial Cancer. 2013;12(3):503–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Wu H, Rusiecki JA, Zhu K, Potter J, Devesa SS. Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer Epidemiol Biomark Prev. 2009;18(7):1945–52.CrossRefGoogle Scholar
  6. 6.
    Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. Arch Pathol Lab Med. 2004;128(7):765.PubMedGoogle Scholar
  7. 7.
    Worthley D, Phillips K, Wayte N, Schrader K, Healey S, Kaurah P, et al. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut. 2012;61(5):774–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Pinheiro H, Oliveira C, Seruca R, Carneiro F. Hereditary diffuse gastric cancer—pathophysiology and clinical management. Best Pract Res Clin Gastroenterol. 2014;28(6):1055–68.CrossRefPubMedGoogle Scholar
  9. 9.
    Lauren P. The two histological main types of gastric carcinoma, an attempt at a histoclinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.CrossRefPubMedGoogle Scholar
  10. 10.
    Hamy A, Letessier E, Bizouarn P, Paineau J, Aillet G, Mirallie E, et al. Study of survival and prognostic factors in patients undergoing resection for gastric linitis plastica: a review of 86 cases. Int Surg. 1998;84(4):337–43.Google Scholar
  11. 11.
    Carneiro F, Huntsman DG, Smyrk TC, Owen DA, Seruca R, Pharoah P, et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol. 2004;203(2):681–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Kaurah P, MacMillan A, Boyd N, Senz J, De Luca A, Chun N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA. 2007;297(21):2360–72.CrossRefPubMedGoogle Scholar
  13. 13.
    Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010;47(7):436–44.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Corso G, Carvalho J, Marrelli D, Vindigni C, Carvalho B, Seruca R, et al. Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer. J Clin Oncol. 2013;2012.2044:4612.Google Scholar
  15. 15.
    Becker K-F, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR, et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res. 1994;54(14):3845–52.PubMedGoogle Scholar
  16. 16.
    Carvalho J, van Grieken NC, Pereira PM, Sousa S, Tijssen M, Buffart TE, et al. Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. J Pathol. 2012;228(1):31–44.PubMedGoogle Scholar
  17. 17.
    Liu Y-C, Shen C-Y, Wu H-S, Hsieh T-Y, Chan D-C, Chen C-J, et al. Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas. World J Gastroenterol. 2006;12(14):2168–73.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Liu X, Chu K-M. E-cadherin and gastric cancer: cause, consequence, and applications. Biomed Res Int 2014.  https://doi.org/10.1155/2014/637308.
  19. 19.
    Van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci. 2008;65(23):3756–88.CrossRefPubMedGoogle Scholar
  20. 20.
    Stemmler MP. Cadherins in development and cancer. Mol BioSyst. 2008;4(8):835–50.CrossRefPubMedGoogle Scholar
  21. 21.
    Oliveira C, Senz J, Kaurah P, Pinheiro H, Sanges R, Haegert A, et al. Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet. 2009;18(9):1545–55.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Yamada M, Fukagawa T, Nakajima T, Asada K, Sekine S, Yamashita S, et al. Hereditary diffuse gastric cancer in a Japanese family with a large deletion involving CDH1. Gastric Cancer. 2014;17(4):750–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Pinheiro HB-CR, Seixas S, Carvalho J, Senz J, Oliveira P, Inácio PGL, et al. Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. Hum Mol Genet. 2010;19:943–52.CrossRefPubMedGoogle Scholar
  24. 24.
    Moran CJJM, McAnena OJ. CDH1 associated gastric cancer: a report of a family and review of the literature. Eur J Surg Oncol. 2005;31:259–64.CrossRefPubMedGoogle Scholar
  25. 25.
    Machado J, Oliveira C, Carvalho R, Soares P, Berx G, Caldas C, et al. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene. 2001;20(12):1525–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Park J-G, Yang H-K, Kim WH, Caldas C, Yokota J, Guilford PJ. Report on the first meeting of the international collaborative group on hereditary gastric cancer. J Natl Cancer Inst. 2000;92(21):1781–2.CrossRefPubMedGoogle Scholar
  27. 27.
    Corso G, Marrelli D, Pascale V, Vindigni C, Roviello F. Frequency of CDH1 germline mutations in gastric carcinoma coming from high-and low-risk areas: metanalysis and systematic review of the literature. BMC Cancer. 2012;12(1):1.CrossRefGoogle Scholar
  28. 28.
    Almasi Z, Rafiemanesh H, Salehiniya H. Epidemiology characteristics and trends of incidence and morphology of stomach cancer in Iran. Asian Pac J Cancer Prev. 2015;16(7):2757–61.CrossRefPubMedGoogle Scholar
  29. 29.
    Oliveira C, Seruca R, Carneiro F. Genetics, pathology, and clinics of familial gastric cancer. Int J Surg Pathol. 2006;14(1):21–33.CrossRefPubMedGoogle Scholar
  30. 30.
    van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015;52(6):361–74.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol. 2015;1(1):23–32.CrossRefPubMedGoogle Scholar
  32. 32.
    Benusiglio PR, Malka D, Rouleau E, De Pauw A, Buecher B, Noguès C, et al. CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. J Med Genet. 2013;50(7):486–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Corso G, Pedrazzani C, Pinheiro H, Fernandes E, Marrelli D, Rinnovati A, et al. E-cadherin genetic screening and clinico-pathologic characteristics of early onset gastric cancer. Eur J Cancer. 2011;47(4):631–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Ghaffari S, Rafati M, Sabokbar T, Dastan J. A novel truncating mutation in the E-cadherin gene in the first Iranian family with hereditary diffuse gastric cancer. Eur J Surg Oncol. 2010;36(6):559–62.CrossRefPubMedGoogle Scholar
  35. 35.
    Sugimoto S, Yamada H, Takahashi M, Morohoshi Y, Yamaguchi N, Tsunoda Y, et al. Early-onset diffuse gastric cancer associated with a de novo large genomic deletion of CDH1 gene. Gastric Cancer. 2014;17(4):745–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Molinaro V, Pensotti V, Marabelli M, Feroce I, Barile M, Pozzi S, et al. Complementary molecular approaches reveal heterogeneous CDH1 germline defects in Italian patients with hereditary diffuse gastric cancer (HDGC) syndrome. Genes Chromosom Cancer. 2014;53(5):432–45.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Pediatric Inherited Diseases Research Center, Research Institute for Primordial Prevention of Non-communicable disease and Department of Genetics and Molecular Biology, School of MedicineIsfahan University of Medical SciencesIsfahanIran
  2. 2.Internal medicine department, School of MedicineIsfahan University of Medical SciencesIsfahanIran
  3. 3.Department of Pathology, School of MedicineIsfahan University of Medical SciencesIsfahanIran

Personalised recommendations